S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Sports analytics may be outnumbered when it comes to artificial intelligence
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Nobel laureate Muhammad Yunus is granted bail in a Bangladesh graft case
NASDAQ:SBFM

Sunshine Biopharma (SBFM) Stock Price, News & Analysis

$0.06
0.00 (0.00%)
(As of 03/1/2024 ET)
Today's Range
$0.05
$0.06
50-Day Range
$0.05
$0.29
52-Week Range
$0.05
$1.40
Volume
13.24 million shs
Average Volume
5.97 million shs
Market Capitalization
$1.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.60

Sunshine Biopharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
4,593.1% Upside
$2.60 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.45mentions of Sunshine Biopharma in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars


SBFM stock logo

About Sunshine Biopharma Stock (NASDAQ:SBFM)

Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals. The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; SBFM-PL4, an anti-coronavirus treatment compound; and K1.1 mRNA molecules used as anti-cancer agents. It also offers Essential 9, an amino acids capsules; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements. Sunshine Biopharma, Inc. is based in New York, New York.

SBFM Stock Price History

SBFM Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
What Are Sunshine Laws? Definition, Purpose, Examples
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Sunshine Biopharma Announces Share Repurchase Program
See More Headlines
Receive SBFM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sunshine Biopharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/13/2023
Today
3/02/2024
Next Earnings (Estimated)
4/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Current Symbol
NASDAQ:SBFM
Fax
N/A
Employees
46
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$2.60
High Stock Price Target
$2.60
Low Stock Price Target
$2.60
Potential Upside/Downside
+4,593.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-26,740,000.00
Net Margins
-131.52%
Pretax Margin
-129.51%

Debt

Sales & Book Value

Annual Sales
$4.35 million
Book Value
$0.96 per share

Miscellaneous

Free Float
11,563,000
Market Cap
$1.42 million
Optionable
Not Optionable
Beta
1.15
7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Mr. Camille Sebaaly (Age 65)
    CFO & Secretary
    Comp: $720k
  • Dr. Steve N. Slilaty Ph.D. (Age 72)
    CEO, President & Chairman
    Comp: $430k
  • Mr. Marc Beaudoin (Age 57)
    Chief Operating Officer
  • Dr. Abderrazzak Merzouki (Age 60)
    Chief Science Officer & Director
    Comp: $545k
  • Mr. Malek Chamoun (Age 39)
    Chief Development Officer
  • Mr. Robert G. Ferreira (Age 62)
    President of Sunshine Bio Investments Inc














SBFM Stock Analysis - Frequently Asked Questions

Should I buy or sell Sunshine Biopharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Sunshine Biopharma in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SBFM shares.
View SBFM analyst ratings
or view top-rated stocks.

What is Sunshine Biopharma's stock price target for 2024?

1 equities research analysts have issued twelve-month target prices for Sunshine Biopharma's shares. Their SBFM share price targets range from $2.60 to $2.60. On average, they expect the company's share price to reach $2.60 in the next year. This suggests a possible upside of 4,593.1% from the stock's current price.
View analysts price targets for SBFM
or view top-rated stocks among Wall Street analysts.

How have SBFM shares performed in 2024?

Sunshine Biopharma's stock was trading at $0.2715 at the beginning of the year. Since then, SBFM stock has decreased by 79.6% and is now trading at $0.0554.
View the best growth stocks for 2024 here
.

Are investors shorting Sunshine Biopharma?

Sunshine Biopharma saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 602,600 shares, an increase of 487.3% from the January 31st total of 102,600 shares. Based on an average daily volume of 1,890,000 shares, the short-interest ratio is currently 0.3 days. Approximately 1.3% of the shares of the company are short sold.
View Sunshine Biopharma's Short Interest
.

When is Sunshine Biopharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, April 2nd 2024.
View our SBFM earnings forecast
.

How were Sunshine Biopharma's earnings last quarter?

Sunshine Biopharma, Inc. (NASDAQ:SBFM) issued its earnings results on Monday, November, 13th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.02. The company had revenue of $5.96 million for the quarter. Sunshine Biopharma had a negative net margin of 131.52% and a negative trailing twelve-month return on equity of 124.32%.

Who are Sunshine Biopharma's major shareholders?

Sunshine Biopharma's stock is owned by many different institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (8.29%) and Citadel Advisors LLC (0.72%).
View institutional ownership trends
.

How do I buy shares of Sunshine Biopharma?

Shares of SBFM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SBFM) was last updated on 3/3/2024 by MarketBeat.com Staff